United Therapeutics Corp (NASDAQ:UTHR) Chief Financial Officer and Treasurer James Edgemond executed a transaction involving the sale of 10,000 shares of the company's common stock on June 8, 2026. The sale, valued at approximately $5.48 million, was conducted pursuant to a pre-arranged Rule 10b5-1 trading plan established on October 31, 2025. Prior to the sale, Edgemond exercised stock options for an equal number of shares at $117.76 per share. This financial activity occurs against a backdrop of mixed corporate developments, including a first-quarter earnings report that fell short of analyst expectations and the successful completion of a Phase 3 clinical study for its Tyvaso product.
The transaction details indicate that the 10,000 shares were sold at prices ranging from $544.41 to $551.77 per share. The total value of these sales amounted to $5,475,044. Before executing the sale, Mr. Edgemond acquired 10,000 shares of common stock by exercising stock options at a price of $117.76 per share, totaling $1,177,600. Both the exercise of stock options and the subsequent sale of shares were executed pursuant to a Rule 10b5-1 trading plan, which Mr. Edgemond established on October 31, 2025. Following these transactions, Mr. Edgemond directly holds 18,876 shares of United Therapeutics common stock.
The sale comes as the stock has delivered a remarkable 68% return over the past year, though InvestingPro analysis suggests the shares are currently trading above their Fair Value. In other recent news, United Therapeutics Corporation reported first-quarter financial results that fell short of analyst expectations. The company announced revenue of $781.5 million, which was below the anticipated $797.4 million. Tyvaso, a significant product for United Therapeutics, generated $457.5 million in revenue, missing the consensus estimate of $478.6 million. Net income for the quarter was $274.9 million, compared to the expected $320.5 million.
United TherapeuticsFollowAnalyze UTHRIncluded in our AI-picked strategies·Review strategies553.14▲+8.45(+1.55%)Closed·15:59:59·USD553.18▲+0.04(+0.01%)After Hours·17:58:111D1W1M6M1Y5YMaxCreated with Highcharts 11.4.814:0015:0016:0017:0018:0019:00540545550Analyze UTHRIn other developments, United Therapeutics announced that its TETON-1 phase 3 study of Tyvaso in idiopathic pulmonary fibrosis met its primary endpoint. The study results, published in the New England Journal of Medicine, showed that Tyvaso preserved lung function and reduced the risk of clinical worsening events. Additionally, United Therapeutics has partnered with Varda Space Industries to explore microgravity-based pharmaceutical processing for rare pulmonary diseases. This collaboration aims to leverage microgravity to improve the formulation of therapeutic compounds.
Furthermore, TD Cowen reiterated its Buy rating for United Therapeutics, setting a price target of $675.00. Meanwhile, BTIG maintained a Neutral rating on the stock following the Q1 earnings miss. These recent developments reflect the ongoing activities and strategic collaborations of United Therapeutics in advancing its pharmaceutical offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.Should you invest $2,000 in UTHR right now?ProPicks AI evaluates UTHR alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if UTHR is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?See More Stocks